These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32902184)

  • 21. First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer.
    Remick JS; Schonewolf C; Gabriel P; Doucette A; Levin WP; Kucharczuk JC; Singhal S; Pechet TTV; Rengan R; Simone CB; Berman AT
    Clin Lung Cancer; 2017 Jul; 18(4):364-371. PubMed ID: 28162946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers.
    Ding XP; Zhang J; Li BS; Li HS; Wang ZT; Yi Y; Sun HF; Wang DQ
    Asian Pac J Cancer Prev; 2012; 13(1):319-23. PubMed ID: 22502693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer.
    Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
    J Radiat Res; 2021 Sep; 62(5):894-900. PubMed ID: 34260719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer.
    Zhou L; Liu J; Xue J; Xu Y; Gong Y; Deng L; Wang S; Zhong R; Ding Z; Lu Y
    Radiat Oncol; 2014 May; 9():117. PubMed ID: 24884773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study.
    Martinussen HM; Reymen B; Wanders R; Troost EG; Dingemans AC; Öllers M; Houben R; De Ruysscher D; Lambin P; van Baardwijk A
    Radiother Oncol; 2016 Nov; 121(2):322-327. PubMed ID: 27884510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer.
    Kong C; Zhu X; Shi M; Wang L; Chen C; Tao H; Jiang N; Yan P; Zhao L; Song X; He X
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):710-719. PubMed ID: 32275994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
    Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography for staging locally advanced cervical cancer and assessing intensity modulated radiotherapy approach.
    Draghini L; Costantini S; Vicenzi L; Italiani M; Loreti F; Trippa F; Arcidiacono F; Casale M; Mantello G; Maranzano E
    Radiol Med; 2019 Sep; 124(9):819-825. PubMed ID: 30904982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?
    Meng Y; Luo W; Xu H; Wang W; Zhou S; Tang X; Li Z; Zhou C; Yang H
    Radiother Oncol; 2021 May; 158():118-124. PubMed ID: 33636232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trial.
    Cui T; Zhang A; Cui J; Chen L; Chen G; Dai H; Qin X; Li G; Sun J
    Radiother Oncol; 2023 Apr; 181():109505. PubMed ID: 36764460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)US-NA information in addition to PET-CT for delineation?
    Peeters ST; Dooms C; Van Baardwijk A; Dingemans AM; Martinussen H; Vansteenkiste J; Decaluwé H; De Leyn P; Yserbyt J; Nackaerts K; De Wever W; Deroose CM; De Ruysscher D
    Radiother Oncol; 2016 Aug; 120(2):273-8. PubMed ID: 27291644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era.
    Vargo JA; Kim H; Choi S; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Beriwal S
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1091-8. PubMed ID: 25303889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy.
    Lazzari R; Riva G; Augugliaro M; Vavassori A; Dicuonzo S; Cattani F; Comi S; Colombo N; Jereczek-Fossa BA
    Int J Gynecol Cancer; 2020 May; 30(5):607-612. PubMed ID: 32188626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
    Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
    J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial.
    Askoxylakis V; Dinkel J; Eichinger M; Stieltjes B; Sommer G; Strauss LG; Dimitrakopoulou-Strauss A; Kopp-Schneider A; Haberkorn U; Huber PE; Bischof M; Debus J; Thieke C
    Radiat Oncol; 2012 Sep; 7():157. PubMed ID: 22974533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer.
    Guckenberger M; Kavanagh A; Partridge M
    Strahlenther Onkol; 2012 Oct; 188(10):894-900. PubMed ID: 22933031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
    Vanuytsel LJ; Vansteenkiste JF; Stroobants SG; De Leyn PR; De Wever W; Verbeken EK; Gatti GG; Huyskens DP; Kutcher GJ
    Radiother Oncol; 2000 Jun; 55(3):317-24. PubMed ID: 10869746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of simultaneous radiation boost achieves high treatment response rate in patients with metastatic gastric cancer.
    Yang J; Liu J; Gao S; Yang Y; Kong W; Ren W; Zhu L; Yang M; Wei J; Zou Z; Qian X; Liu B; Yan J
    J Cancer Res Ther; 2018 Jan; 14(1):36-39. PubMed ID: 29516956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results.
    King SC; Acker JC; Kussin PS; Marks LB; Weeks KJ; Leopold KA
    Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):593-9. PubMed ID: 8948343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High dose simultaneous integrated boost for node positive cervical cancer.
    Jayatilakebanda I; Tsang YM; Hoskin P
    Radiat Oncol; 2021 May; 16(1):92. PubMed ID: 34001158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.